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Chemosensitive Follicular Non-Hodgkin Lymphoma
beyond First Complete Response or
First Partial Response
Marcie R. Tomblyn,1,9 Marian Ewell,2 Christopher Bredeson,3 Brad S. Kahl,4
Stacey A. Goodman,5MaryM.Horowitz,6 JulieM. Vose,7 Robert S. Negrin,8 GinnaG. Laport8,9Patients with follicular lymphoma (FL) typically experience an indolent course; however, the disease is rarely
curable with conventional chemotherapy. Autologous hematopoietic cell transplantation (HCT) can extend
progression-free survival (PFS) and overall survival (OS), but relapse is the primary cause of failure. Alloge-
neic HCT confers lower relapse rates due to a graft-versus-lymphoma effect. Reduced-intensity conditioning
(RIC) allows the performance of allogeneic HCTwith lower toxicity. The Blood and Marrow Transplant Clin-
ical Trials Network conducted a prospective multicenter trial comparing these two strategies in patients with
relapsed, chemotherapy-sensitive FL. Patients were assigned to a treatment arm based on the availability of
an HLA-matched sibling donor (MSD). Those with an MSD underwent allogeneic HCT (n5 8) with the FCR
preparative regimen (fludarabine, cyclophosphamide [Cy], rituximab [RTX]) and received tacrolimus and
methotrexate for graft-versus-host disease (GVHD) prophylaxis. Those without an MSD (n 5 22) under-
went mobilization with Cy, RTX, and filgrastim and received a conditioning regimen of either CBV (Cy,
carmustine, Etoposide [VP16]) or total body irradiation with Cy and VP16. Patients undergoing autologous
HCTreceived 4 doses of weekly maintenance RTX (375 mg/m2) starting on day142 post-HCT. Sixteen pa-
tients were in complete remission, 10 patients were in partial remission, and 1 patient had stable disease after
salvage therapy and before HCT. Median follow-up was 36 months (range, 1-51 months). OS was 73% in au-
tologous HCT versus 100% in allogeneic HCT, and PFS was 63% in autologous HCT versus 86% in allogeneic
HCT. No patient had grade II-IV acute GVHD; two patients developed extensive chronic GVHD. Three au-
tologous recipients died from nonrelapse causes. This trial closed early because of slow accrual. We show
that the FCR regimen is well tolerated, and that both allogeneic and autologous HCT result in promising
3-year OS and PFS in patients with relapsed FL.
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Follicular lymphoma (FL) is the second most
common type of non-Hodgkin lymphoma, with an in-
cidence of 15,000 new cases/year in the United
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a continuous pattern of relapse typically occurs, result-
ing in progressively shorter remission durations, with
patients invariably succumbing to their disease [1].
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diagnosed FL or patients in first remission yielded high
response rates but did not confer improved overall sur-
vival (OS) compared with conventional chemotherapy,
due in part to the higher incidence of myelodysplastic
syndrome in these patients [2-4]. In patients with
relapsed FL, one randomized trial, the CUP trial,
demonstrated a survival advantage in patients who
received high-dose chemotherapy compared with those
who received conventional therapy at relapse [5].
Relapse/progression after autologous HCT continues
to be the leading cause of treatment failure, however [6].
Allogeneic HCT after myeloablative conditioning
regimens is sometimes offered to patients with recurrent
FLwith the goal of harnessing a graft-versus-lymphoma
effect and to circumvent the tumor cell contamination
associated with autologous hematopoietic stem cell har-
vests [7-10]. Retrospective data indicate a significantly
lower risk of relapse compared with autologous HCT,
but this benefit is invariably offset by the treatment-
related mortality associated with this approach [8,9].
Allogeneic HCT with reduced-intensity condition-
ing (RIC) regimens are increasingly used, with the goal
of reducing nonrelapse mortality while still taking
advantage of graft-versus-lymphoma effects. Results
appear to be promising, with event-free survival ranging
from 51% to 85% in studies with follow-up times of 2-6
years [11-16]. The Blood and Marrow Transplant
Clinical Trials Network (BMT CTN) conducted a
prospective study comparing the efficacy of autologous
HCT versus RIC allogeneic HCT for patients with FL
beyond first complete response or first partial response.
Treatment allocation was by biological assignment.
Patients with an available HLA-matched sibling were
assigned to the allogeneic HCT arm, and those without
anHLA-matched sibling received autologousHCT fol-
lowed bymaintenance therapywith rituximab.Unfortu-
nately, due to slow accrual, this trial closed before
enrollment was completed. Here, we report the out-
comes of the 30 patients enrolled on this multicenter
trial.METHODS
Patients
Patients up to age 75 years with histologically
confirmed grade I or II Revised European-American
Lymphoma classification [17] FL were eligible for en-
rollment if they were in first relapse or beyond. All pa-
tients were required to have chemotherapy-sensitive
disease, defined as \20% marrow involvement and
either all lymph nodes smaller than 3 cm in axial diam-
eter or a.75% reduction in total lymph node volume
by bidimensional measurements with the most recent
chemotherapy. Patients were ineligible if they had
received previous autologous or allogeneic HCT ormore than 4 previous treatment regimens, excluding
involved-field radiation or single-agent monoclonal
antibodies. Patients with evidence of transformation
were excluded.
Other eligibility criteria included adequate organ
function, defined as a cardiac ejection fraction of$45%;
total bilirubin less than twice the upper limit of normal;
aspartate and alanine serum transaminases less than 3
times the upper limit of normal; creatinine clearance
.40 mL/min; and CO diffusion capacity, forced expi-
ratory volume in 1 minute, and forced vital capacity all
.50% of normal after adjustment for hemoglobin
level. Patients had to be seronegative for human immu-
nodeficiency virus and could not be pregnant or breast-
feeding. Patients with uncontrolled infections, defined
as progressing on appropriate antimicrobial therapy,
were ineligible. Donors of allogeneic cells were in-
eligible if they were seropositive for hepatitis B, hepati-
tis C, or human immunodeficiency virus infections;
were pregnant or breast-feeding; or were otherwise
medically ineligible to receive filgrastim (Neupogen;
AMGEN, Thousand Oaks, CA) and undergo leuka-
pheresis of peripheral blood progenitor cells.
Study Design
This was amulticenter biological assignment study
[18] in which patients with an HLA-identical sibling
received a RIC allogeneic HCT, and all other patients
received autologous HCT after high-dose therapy.
HLA matching was defined as a minimum of a low-
resolution match at HLA-A and HLA-B and a high-
resolution match at HLA-DRB1. The study protocol
and informed consent were approved by the National
Heart Lung and Blood Institute’s Protocol Review
Committee and Data and Safety Monitoring Board,
as well as the Institutional Review Boards of all partici-
pating institutions. All patients provided informed
consent in accordance with the Declaration of Helsinki.
This study is registered at http://www.clinicaltrials.gov
as NCT00096460.
Study Treatment
Cytoreduction/Mobilization
All patients, regardless of planned autologous or
allogeneic HCT, received chemotherapy with rituxi-
mab (Genentech, San Francisco, CA) 375 mg/m2 i.v.
on days 1 and 8 and cyclophosphamide 4000 mg/m2
i.v. on day 2 within 6 weeks after enrollment. Patients
assigned to the autologous HCT arm received filgras-
tim 10 mg/kg/day s.c. as a single daily dose or divided
daily doses starting 2 days after cyclophosphamide
and continuing until leukapheresis was completed.
Collection of a minimum of 1.0  106 CD341 cells/
kg (goal, 2.0  106 CD341 cells/kg) was required to
proceed to high-dose chemotherapy. Patients with
a matched sibling donor received filgrastim 5 mg/kg/
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phil count was .500/mm3 for 3 days.
Autologous HCT conditioning
Patients received either a total body irradiation–
based conditioning regimen or a chemotherapy-only
conditioning regimen. The centers declared the condi-
tioning regimen at the time of study activation. Patients
aged $60 years received only a chemotherapy-based
regimen.
Conditioning was provided with either 1,3-Bis(2-
chloroethyl)-1-nitrosurea (BCNU) 15 mg/kg (not to
exceed 550 mg/m2) on day -6, etoposide (VP16) 60
mg/kg on day -4, and cyclophosphamide 100 mg/kg
on day -2 (n5 6) or fractionated total body irradiation,
1200 cGy on days -8, -7, -6, and -5; VP16 60 mg/kg on
day -4; and cyclophosphamide 100 mg/kg on day -2 (n
5 14). Patients then received autologous peripheral
blood progenitor cell infusion on day 0, followed by
filgrastim 5 mg/kg/day starting on day15 until the ab-
solute neutrophil count was.500/mm3 for 3 days. Pa-
tients received rituximab maintenance therapy (375
mg/m2/day i.v.) weekly for 4 doses starting between
day142 and day175 after autologousHCT, provided
that they had adequate renal and liver function test pa-
rameters, were fully recovered frommucositis, and did
not have active Cytomegalovirus or fungal infection.
Allogeneic HCT conditioning
Patients received conditioning with both fludara-
bine 30 mg/m2/day i.v. and cyclophosphamide 750
mg/m2/day i.v. on days -6, -5, and -4 and rituximab
375 mg/m2/day i.v. on days -13, -6, 11, and 18. Pe-
ripheral blood progenitor cells were infused on day 0.
All sibling donors received filgrastim 16 mg/kg/day
s.c. for 5 doses. Leukapheresis commenced on day -1 of
the recipient’s conditioning regimen and continued
until at least 2  106 CD341 cells/kg were collected,
or a maximum of 3 aphereses. If fewer than 1  106
CD341 cells/kg were collected after the third leuka-
pheresis, then the patientwasmanaged at the discretion
of the treating physician. Although this did not occur,
these patientswere tobe removed from the trial therapy
and followed for relapse, progression, and survival.
GVHD prophylaxis after allogeneic HCT
Tacrolimus 0.09 mg/kg/day orally, based on actual
body weight, was initiated on day -2, with adjustment
to maintain a serum trough level of 5-15 ng/mL and
methotrexate 5 mg/m2/day i.v. on days11,13, and16
were administered for GVHD prophylaxis. A taper of
tacrolimus was initiated on day 190 and completed by
day1180unless grade III or IV acuteGVHDdeveloped.
Supportive care
All patients received antimicrobial prophylaxis and
blood product support in accordance with the BMTCTNManual of Procedures [19]. The use of hemato-
poietic growth factors after HCT, supplemental i.v.
immune globulin, and immunizations were adminis-
tered in accordance with institutional guidelines.
Follow-up and Disease Response
Disease response was assessed based on the criteria
ofCheson et al. [20]. Before the initiation of cytoreduc-
tion/mobilization chemotherapy, all patients under-
went disease staging with CT scans and bone marrow
biopsy. These tests were repeated within 2 weeks be-
fore the initiation of conditioning. Patients undergoing
autologousHCTwere restaged before the initiation of
rituximab maintenance. Thereafter, all patients, re-
gardless of donor source, were restaged at 12 weeks, 6
months, 1 year, 2 years, and 3 years after HCT.
Additional assessments for toxicity and GVHD
were performed in accordance with protocol require-
ments. Specifically, toxicity was assessed at 4 weeks af-
ter rituximab administration during the cytoreduction/
mobilization phase of the study, as well as at 4, 8, and 12
weeks afterHCT.Additional toxicity assessments were
performed at 6 months after HCT and every 6 months
thereafter up to 3 years after HCT. All toxicities were
assessed using the National Cancer Institute’s Com-
mon Terminology Criteria for Adverse Events v3
[21]. GVHD was assessed in patients receiving alloge-
neic HCT weekly from day 0 through 14 weeks post-
HCT and then at 6 months, 1 year, 2 years, and 3 years
after HCT. Acute GVHD and chronic GVHD were
scored using consensus criteria [22,23].
Statistical Analysis
The primary objective of this trial was to compare
progression-free survival (PFS) at 3 years in patients re-
ceiving high-dose therapy with autologous HCT and
those with an HLA-identical sibling receiving RIC allo-
geneic HCT. It was estimated that 80 patients would be
accrued to the allogeneicHCTarmandbetween250and
400 patients would be accrued to the autologous HCT
arm in the same time period, based on the likelihood of
having a suitable sibling donor. The trial was terminated
early because of slow accrual, and the analysis is limited
to descriptive outcomes of the two arms, with no com-
parisons or multivariate analyses. The cumulative inci-
dence function with competing-risks analysis was used
to estimate relapse and transplantation-relatedmortality
(TRM) [24].TRMwasdefinedasdeathwithout evidence
of disease relapse or progression. OS and PFS were
estimated using the Kaplan-Meier method [25].RESULTS
Patient Characteristics
A total of 30 patients were enrolled on this trial
between August 2004 and February 2006. Of these,
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were assigned to the allogeneic HCT arm, and 22 pa-
tients (73%) were assigned to the autologous HCT
arm. Three patients (10%) did not undergo HCT;
two patients (one autologous, one allogeneic) with-
drew consent before the start of therapy, and one pa-
tient on the autologous arm failed to collect the
minimum 1  106 CD341 cells/kg in 3 leukapheresis
procedures. Pertinent patient characteristics are sum-
marized in Table 1.
Engraftment and Chimerism
Data on CD341 cell dose infused and time to neu-
trophil engraftment were available for 19 of the 20 pa-
tients receiving autologous HCT and all 7 patients
receiving allogeneic HCT. The median cell dose in-
fused was 2.9  106 CD34 cells/kg for the autologous
HCT recipients and 6.8  106 CD341 cells/kg for the
allogeneic transplant recipients. Neutrophil engraft-
ment occurred at a median of 11 days (range, 9-14
days) after autologous HCT and at a median of 10
days (range, 5-13 days) after allogeneic HCT.
Patients in the allogeneic HCT arm underwent
chimerism assessment on day 128, day 156, day
184, 6 months, and 1 year posttransplantation. At 28
days posttransplantation, a median of 88% (range,
66%-100%) of cells were donor-derived; this increased
to 95% (range, 68%-100%) by day 84 and remained
.95% up to the 1-year time point. There were no
engraftment failures.
Response to Transplantation
Disease status was evaluated at the time of en-
rollment (Table 1) as well as immediately beforeTable 1. Characteristics of Patients Enrolled on the BMT
CTN 0202 Clinical Trial by Treatment Arm
Autologous
(n 5 22)
Allogeneic
(n 5 8)
Age, years, median (range) 50 (36-66) 48 (40-64)
Male sex, n (%) 10 (45) 5 (63)
Karnofsky Performance Status, n (%)
100% 8 (36) 1 (13)
90% 12 (55) 5 (63)
#80% 2 (9) 2 (25)
Disease status at enrollment, n (%)
Relapse
First 2 (9) 0
Second 1 (5) 0
Third 1 (5) 0
Partial remission
Second 8 (36) 3 (38)
Third 3 (14) 1 (13)
Complete remission
Second 6 (27) 3 (38)
Third 1 (5) 1 (13)
Number of previous therapies, median
(range)
2 (1-3) 2 (1-3)
Time from diagnosis to transplantation,
months, median (range)
39.8 (9.8-110.5) 28.9 (16.2-64.7)
Follow-up after transplantation,
months, median (range)
36.1 (1.0-50.8) 36.2 (33.2-48.8)transplantation. Among the 20 patients who received
autologous HCT, 12 (60%) were in complete remis-
sion (CR), 7 (35%) were in partial remission (PR),
and 1 (5%) had stable disease at the time of transplan-
tation. At the time of allogeneic HCT, 4 patients were
in CR (57%) and 3 were in PR (43%). Disease re-
sponses were assessed at 3 time points during the first
year post-HCT. Disease response to therapy was not
evaluable in 2 patients on the autologous HCT arm
due to death before day 128 posttransplantation.
Two patients in the autologous HCT arm (1 in CR
and 1 in PR at the time of transplantation) had
disease progression as the best response to therapy.
Following autologous HCT for either PR or stable
disease (n 5 8), 7 patients (88%) achieved CR. All 3
patients receiving allogeneic HCT in PR achieved CR.
Toxicities
Fifteen autologous HCT recipients (75%) and 4
allogeneic HCT recipients (57%) had grade 3-5 toxic-
ities reported in the first year posttransplantation.
Toxicity events included elevated liver enzymes and
bilirubin, vascular leak, hemorrhage, pulmonary
symptoms including pneumonitis, mucositis, and de-
layed neutropenia (Table 2). One case of fatal pneu-
monitis occurred before day 28 after autologous
HCT. The estimated cumulative incidences of TRM
after autologous HCT were 15% (95% confidence
interval [CI], 0-31%) at 1 year and 21.8% (95% CI,
0-35%) at 3 years. No deaths occurred following allo-
geneic HCT.
GVHD
Acute GVHD was assessed weekly after allogeneic
HCT. None of the 7 patients receiving allogeneic
HCT developed grade II-IV acute GVHD. Three pa-
tients were diagnosed with grade I acute GVHD.
Chronic GVHD occurred in 4 patients, at a median
of 244 days post-HCT (range, 161-368 days). The
maximum severity of chronic GVHD was mild in 2
patients and moderate in 2 patients.
Relapse
The cumulative incidence of relapse at 3 years was
similar in the autologous and allogeneic HCT arms
(autologous, 15.4% [95% CI, 0-26.5%]; allogeneic,
14.3% [95% CI, 0-28%]). However, relapses after au-
tologous HCT occurred earlier after transplantation,
with all relapses observed in the first 2 years. The
only patient who relapsed following allogeneic HCT
did not do so until nearly 3 years after transplantation.
Survival
Median follow-up was 36 months after HCT
(range, 1-51 months). The 3-year probability of PFS
following allogeneic HCT was 85.7% (95% CI,
Table 2. Summary of Grade 3/4 Toxicities Reported During the First Year After Autologous and Allogeneic HCT
Days 0-28 Days 29-56 Days 57-84 Day 85 to 6 months 6 months to 1 year
Event Autologous Allogeneic Autologous Allogeneic Autologous Allogeneic Autologous Allogeneic Autologous Allogeneic
Increased ALT 1 1 0 0 0 2 0 0 0 0
Increased AP 0 1 0 0 0 1 0 0 0 0
Increased bilirubin 2 1 0 0 0 0 0 0 0 0
Pneumonitis 1 0 0 0 1 0 1 0 0 0
Dyspnea 1 0 1 0 2 0 2 0 0 0
Hypoxia 2 0 0 0 1 0 0 0 0 0
Hemorrhage 1 0 0 0 0 0 0 0 0 0
Vascular leak 1 0 0 0 0 0 0 0 0 0
Hypotension 2 0 0 0 1 0 0 0 0 0
Mucositis 4 0 0 0 1 0 0 0 0 0
Neutropenia 1 0 4 0 2 0 1 0
ALT indicates alanine aminotransferase; AP, alkaline phosphatase.
Neutropenia was not considered an event until after day 28.
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gous HCT was 62.7% (95% CI, 43.8%-89.6%). The
3-year probability of OS was 100% after allogeneic
HCT and 73.3% (95% CI, 55.6%-100%) after auto-
logous HCT (Figure 1).Figure 1. OS (A) and PFS (B) after allogeneic and autologous HCT
for FL.DISCUSSION
We report the outcomes of 30 patients with
chemosensitive, relapsed FL who underwent either
high-dose therapy with autologous HCT or RIC allo-
geneic HCT with assignment to treatment arm based
on the availability of an HLA-matched sibling donor.
This represents the first and only trial to date that
has attempted to prospectively compare the efficacy
of autologousHCT versus RIC allogeneicHCT in pa-
tients with relapsed FL.Unfortunately, this trial closed
prematurely because of slow patient accrual. Analysis
of the reasons for poor accrual indicated a lack of
equipoise for the two treatments being tested. There
also was a general concern about the potential for
treatment-related morbidity and mortality after allo-
geneic HCT in this older patient population. Conse-
quently, some clinicians favored the use of allogeneic
HCT for patients considered to be at very high risk
of recurrence and autologous HCT for others, making
them reluctant to enroll patients in a trial that could
assign to either therapy.
With approximately 3 years of median follow-up, 1
patient in the allogeneic HCT arm and 3 patients in
the autologous HCT arm have relapsed. This observa-
tion adds to the growing literature supporting the ex-
istence of a robust graft-versus-lymphoma effect
against FL. In addition, there were no cases of TRM
or grade II-IV acute GVHD in the allogeneic HCT
arm. Three patients in the autologous HCT arm
died fromTRM (1 from pneumonitis and 2 from infec-
tion). All allogeneic HCT recipients remain alive at
a median of 36 months post-HCT (range, 33-49
months). Definitive conclusions comparing theefficacy of one treatment arm over the other cannot
be drawn, however, because of the limited sample size.
Of the many treatment options available to pa-
tients with FL, allogeneic HCT remains the only
known cure. Two large retrospective registry analyses
demonstrated lower relapse rates in FL patients after
1056 Biol Blood Marrow Transplant 17:1051-1057, 2011M. R. Tomblyn et al.allogeneic HCT versus after autologous HCT, but
prohibitive TRM after myeloablative allogeneic
HCT impedes long-term survival [8]. Another registry
analysis from the Center for International Blood and
Marrow Transplant Research compared the post-
HCT outcome in FL patients receiving a myeloabla-
tive regimen and those receiving an RIC regimen
[11]. Interestingly, there were no significant differ-
ences in OS, PFS, or TRM in the two groups of
patients, but the RIC patients had a significantly
higher risk of disease progression. Compromised per-
formance status and chemoresistant disease adversely
affected survival and increased the risk of TRM. A
report from Princess Margaret Hospital of 37 FL pa-
tients who received allogeneic HCTwith a myeloabla-
tive regimen reported a 5-year TRMof only 15%, with
an OS of 79% and a PFS of 76% [10]. This is an excep-
tionally low TRM considering that an ablative regi-
men was used, and it can be explained in part by the
fact that all patients were chemosensitive and the me-
dian age was only 45 years old.
RIC allogeneic regimens are increasingly offered to
FL patients, with the goal of making use of the graft-
versus-lymphoma effect while ameliorating the pro-
hibitiveTRMassociated withmyeloablative allogeneic
HCT. Four prospective studies have reported favor-
able and encouraging results with some studies also in-
cluding patients who had failed a previous autologous
HCT [12-15]. All 4 of these studies incorporated
fludarabine-based preparative regimens. The most fa-
vorable data so far originated from theM.D. Anderson
Cancer Center, in a trial in which 47 patients with re-
lapsed FL with chemosensitive disease received the
FCR (fludarabine, cyclophosphamide, rituximab) con-
ditioning regimen used in our study [14]. With a me-
dian follow up of 60 months, the OS and EFS were
85% and 83%, respectively. The TRM was 15%,
with infection being the leading cause of death. Only
2 patients relapsed, and no patients died of progressive
disease. In a recently published report, the GEL-
TAMO group detailed the outcomes of 37 patients
with FLwho received allogeneicHCT after condition-
ing with fludarabine and melphalan [13]. Remission
status at the time of HCT significantly impacted both
OS and TRM. The 4-year OS was 71% for patients
in CR, 48% for those in PR, and 28% for those with
progressive disease, with respective TRMs of 26%,
33%, and 71%. The relapse incidence was only 8%
for all patients. Several retrospective studies of RIC
allogeneic HCT in FL patients have reported PFS
ranging from 38% to 77% with follow-up intervals of
1-3 years [16,26-29]. TRM was considerably higher
than in the aforementioned prospective studies,
however. Such disparities can be explained in part by
patient selection, given that some studies included
a higher proportion of refractory patients, whereas
other studies allowed only chemosensitive patients.In the present study, the 3-year OS and PFS after
autologous HCT were 73% and 63%, respectively,
which compares favorably with the rates in previous
autologous reports with relapsed FL patients. The
use of rituximab represents a distinctive feature of
our trial. We incorporated rituximab during mobiliza-
tion as in vivo purging of the graft and as maintenance
therapy after autologous HCT as a means of eradicat-
ing minimal residual disease [30,31]. Three patients
have relapsed to date, with all 3 relapses occurring
within 2 years of autologous HCT.
Previous reports have consistently shown im-
proved disease-free survival with autologous HCT
compared with conventional salvage therapy, but
only one study to date has shown a beneficial effect
on OS [5]. The CUP trial from Europe was the first
randomized trial that prospectively addressed the
role of autologous HCT versus conventional salvage
chemotherapy. A total of 140 patients with relapsed,
chemosensitive FL were randomized to chemotherapy
alone, to autologous HCT with a purged graft, or to
autologous HCT with an unpurged graft. The 4-year
OS for these 3 groups was 46%, 71%, and 77%, re-
spectively. There was a significant reduction in hazard
rates for both PFS and OS in the chemotherapy group
compared with the combined autologous HCT
groups. There were too few patients in the two HCT
arms to allow assessment of the effect of ex vivo purg-
ing. In contrast to our study, the patients in the CUP
trial were rituximab-na€ıve and did not receive rituxi-
mab during the peritransplantation period, because
the trial was initiated before rituximab use became
routine.
In summary, our results indicate promising out-
comes with both autologous HCT and RIC allogeneic
HCT in FL patients with relapsed disease. Unfortu-
nately, the present trial had to close early due to slow
accrual, as did the CUP trial, the only other published
randomized trial for relapsed FL patients. The avail-
ability of numerous alternative nontransplantation
therapies for patients with advanced FL most likely
explains the poor accrual. Based on our results, we
cannot definitively conclude which arm is more effica-
cious, but the low relapse rate and TRM seen in the
allogeneic HCT arm and reported in previous RIC
allogeneic studies lends compelling support to a fur-
ther study of this modality. Consequently, the BMT
CTN has embarked on a phase II multicenter trial
for relapsed FL patients with the goal of validating
the highly promising results from the FCR regimen
in the allogeneic HCT setting. This ongoing trial
(BMT CTN #0701; Clinicaltrials.gov NCT00912223)
is being conducted with the upfront participation of
3 National Cancer Institute cancer cooperative groups
(Cancer and Leukemia Group B, Southwest On-
cology Group, and Eastern Cooperative Oncology
Group).
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